Sturdy monetary momentum: Viemed reported >172,000 sufferers, a 26% CAGR since going public, $270M income and $28M free money movement in 2025, stays internet debt-free, and guided 2026 income of $310–$320M with EBITDA of $65–$69M.
Fast diversification away from ventilators: Air flow fell from 87% of income in 2019 to 48% in the present day as sleep (now 21% of internet income), oxygen, airway clearance, maternal well being and staffing have expanded—CPAP affected person progress rose 62% in 2025 and administration is “doubling down” on sleep.
Giant underserved market and bettering regulatory backdrop: Administration cites roughly 1.25M Medicare candidates for advanced respiratory care however solely ~70,000 handled (≈6% penetration), and famous favorable coverage strikes together with a brand new ventilator NCD and CMS exclusions from aggressive bidding that cut back reimbursement uncertainty.
Inquisitive about Viemed Healthcare, Inc.? Listed below are 5 shares we like higher.
Viemed Healthcare (NASDAQ:VMD) executives outlined the corporate’s home-based respiratory care mannequin, current monetary efficiency, and progress priorities throughout a current investor presentation, emphasizing an increasing service combine, continued natural progress, and what administration characterised as an bettering regulatory backdrop.
Administration mentioned Viemed focuses on treating advanced respiratory sufferers within the house, aiming to cut back emergency room visits and hospitalizations and assist hospitals handle readmissions and size of keep. The corporate mentioned it serves as a hyperlink between payers, physicians, and sufferers by navigating care supply within the house utilizing a mix of in-home know-how and respiratory therapist assist.
→ Expedia Inventory Turns Risky After Rally. The place Does It Go Subsequent?
Viemed reported having greater than 172,000 sufferers underneath care throughout all 50 states, with what it described as “first rate protection” in roughly 37 to 38 states and extra room to densify and develop geographically. The corporate mentioned it has grown at a 26% compound annual progress price since going public and generated $28 million of free money movement in 2025 whereas sustaining no internet debt.
On its core ventilator providing, administration mentioned the month-to-month reimbursement is about $1,050 from Medicare, with most personal insurers following an analogous mannequin. The corporate described the reimbursement construction as an “uncapped rental” bundled price that features 24/7 in-home respiratory care, provides, and tools. Executives cited a median affected person size of keep of 17 months, noting affected person period can differ.
→ The S&P 500 Broke Its 200-Day Shifting Common—This is What to Anticipate
Administration highlighted what it sees as a big underserved COPD inhabitants. Executives mentioned the U.S. has about 25 million folks with COPD, with about 10%—or 2.5 million—on the most extreme degree. Viemed estimated roughly half of these extreme instances attain power respiratory failure and turn out to be candidates for advanced respiratory providers. The corporate mentioned there are about 1.25 million such sufferers in Medicare, whereas the trade has handled about 70,000 Medicare beneficiaries, which administration characterised as roughly 6% penetration in Medicare and “sub-10%” when together with personal insurance coverage. Viemed mentioned it’s the third-largest supplier within the area, representing about 14% market share, and that the highest 10 suppliers comprise 62% of the market.
Viemed mentioned it makes use of in-house know-how deployed in sufferers’ houses, together with a pill interface that connects to ventilators and different tools, permits distant readings, and helps telehealth interactions with respiratory therapists throughout episodes reminiscent of shortness-of-breath assaults. Administration mentioned the corporate captures knowledge and outcomes to report again to physicians and payers.
→ The SkyWater Deal: IonQ’s Bid for Quantum Supremacy
Executives additionally referenced three research the corporate has accomplished within the area, citing themes that embrace lowered emergency room visits and hospitalizations. Administration mentioned the research confirmed a 43% relative mortality discount and a 39% relative discount in all-cause mortality over seven years, and recommended potential financial savings of greater than $5,400 per affected person per yr by initiating therapies earlier.
The corporate described its working mannequin as lean and scalable, emphasizing that it doesn’t usually require a conventional sturdy medical tools (DME) footprint reminiscent of retail shops. As an alternative, it depends on a cellular workforce, with therapists carrying stock of their automobiles and utilizing knowledge to focus on “COPD needy wealthy environments” based mostly on prevalence and readmission patterns.
Administration mentioned it has broadened its service combine in recent times, including platforms in sleep, maternal well being, and staffing alongside advanced respiratory providers. Viemed listed extra choices that embrace airway clearance gadgets (reminiscent of percussion vests), stationary and transportable oxygen concentrators, sleep apnea CPAP remedy with recurring resupply income, and breast pumps.
Executives mentioned a July 1 acquisition of Lehan’s Medical in Illinois, describing it as 60% maternal well being and 40% respiratory, and mentioned the corporate is including breast pumps and expects maternal well being to develop in 2026 and past.
Administration introduced a income combine shift from 2019 to the present interval, stating that air flow represented 87% of income in 2019 and is now 48%. The corporate mentioned oxygen represents 8% of income, airway clearance 7%, sleep 21%, maternal well being 6%, and healthcare staffing 8%.
On sleep, administration described it as one of many firm’s fastest-growing segments. Executives mentioned that in 2025 CPAP affected person progress elevated 62% and resupply grew 49%, with sleep reaching 21% of internet income by the fourth quarter of 2025. The corporate attributed sleep progress to acquisitions, salesforce growth, and demand for sleep apnea therapy, and mentioned it’s “doubling down” on sleep in 2026. Administration put the addressable U.S. sleep market at greater than 30 million sufferers.
The staffing enterprise, which administration mentioned was added post-COVID amid a medical labor scarcity, has advanced into state-by-state contracts. Executives mentioned about 80% of staffing now has a behavioral well being part, together with putting licensed medical social staff for particular initiatives.
In a overview of 2025 efficiency, administration mentioned Viemed ended the yr with simply over $270 million in income and over $60 million of EBITDA. Executives mentioned the corporate stays internet debt-free, with roughly as a lot money as debt, and famous it has been paying down debt taken on for the Lehan’s acquisition.
Administration additionally mentioned buybacks, stating the corporate executed its third repurchase program final yr and purchased again 5% of fairness. Executives mentioned Viemed has repurchased 4.5 million shares at a median worth of $5.79 and just lately launched one other buyback.
For 2026, administration offered steerage of $310 million to $320 million in income and $65 million to $69 million of EBITDA. Executives mentioned EBITDA progress trails income partly as a result of 2025 included a number of million {dollars} of positive aspects associated to a ventilator buyback program. Administration mentioned gross margins have compressed barely over time as a result of diversification throughout product traces, whereas EBITDA margins have been comparatively secure. The corporate additionally mentioned it has been worthwhile on a internet earnings foundation yearly since going public.
Executives mentioned most progress has been natural, estimating that of the $270 million in 2025 income, roughly $50 million was acquired. They described Viemed as “sales-driven,” centered on recruiting salespeople and therapists in underserved markets, whereas additionally pursuing disciplined M&A with administration groups that may assist develop product traces or enhance advanced respiratory capabilities.
Administration mentioned it’s utilizing AI instruments throughout departments and expects this to sluggish the tempo of future hiring. Executives additionally emphasised declining capital expenditure depth, noting the ventilator enterprise—traditionally the very best CapEx space—has matured as the corporate reaches roughly 12,000 to 13,000 lively ventilator sufferers. They mentioned progress in CPAP resupply and maternal well being is relatively low- to zero-CapEx, supporting expectations for increased free money movement past the $28 million generated in 2025.
Administration highlighted what it described as supportive regulatory tailwinds towards home-based care and cited demographic developments, together with an estimated 10,000 child boomers turning 65 every day by way of 2030. Executives additionally mentioned CMS has indicated that the merchandise Viemed presents might be excluded from aggressive bidding, which administration mentioned reduces uncertainty for traders.
The corporate mentioned a brand new ventilator Nationwide Protection Willpower (NCD) introduced in June, describing it as offering clearer guidelines and decreasing ambiguity round protection necessities. Administration mentioned this readability will help forestall denials from Medicare Benefit plans and that the corporate is already seeing a behavioral shift from payers.
On reimbursement developments, executives mentioned current modifications have largely been CPI-linked will increase. They cited traditionally increased CPI bumps following COVID (together with 5% and eight% in sure intervals) and mentioned the present yr’s improve is roughly 2% to 2.8% relying on product and geography, with expectations for one more CPI adjustment heading into 2027.
Viemed Healthcare, Inc (NASDAQ: VMD) is a supplier of home-based respiratory remedy providers, specializing within the administration of sufferers requiring long-term mechanical air flow and pulmonary assist. The corporate’s choices embody invasive and noninvasive air flow, airway clearance therapies, cough help gadgets, and supplemental oxygen. Viemed combines sturdy medical tools with medical care, delivering tailor-made respiratory therapy plans which are overseen by licensed respiratory therapists and registered nurses.
Based within the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve sufferers throughout a number of states in the USA.
The article “Viemed Healthcare Highlights Development, Diversification and 2026 Steering at Investor Convention” was initially revealed by MarketBeat.
